Afuresertib

Drug Profile

Afuresertib

Alternative Names: 2110183; Afuresertib hydrochloride; ASB183; GSK-2110183; GSK2110183B; GSK2110183C

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Novartis Oncology; University Health Network
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Small molecules; Thiophenes
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Haematological malignancies; Histiocytosis
  • Phase I/II Multiple myeloma; Ovarian cancer; Solid tumours
  • Phase I Cancer; Gastric cancer

Most Recent Events

  • 05 Oct 2016 GlaxoSmithKline withdraws a phase I trial in Prostate cancer in USA prior to enrolment (NCT02380313)
  • 18 Jul 2016 Biomarkers information updated
  • 06 May 2016 Pharmacodynamics data from a preclinical study presented at the at 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top